Compare

GHK-Cu vs PT-141

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

GHK-Cu

1253 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 47% · Mixed 40% · Unfavorable overall 13%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Lean mass
-156
Joint comfort
-77
Recovery
-45
Digestive comfort
4
Skin appearance
11

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Appetite loss
-60
Injection site reaction
3
Anxiety
-80
Flushing
0
Headache
10

Self-reported dose per injection

Median bucket: 200–400 mcg · Most common: 200–400 mcg

Reports span 25–1000 mcg

25–50
2
50–100
9
100–200
16
200–400
23
400–600
12
600–1000
7

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing17stacking15side effects13ghk-cu11

How repeat users are trending

Among repeat reporters, 57% said they felt similar to their last entry, 39% more positive, and 17% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 19 days · Based on 276 repeat reporters

PT-141

1941 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 45% · Mixed 38% · Unfavorable overall 17%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Skin appearance
-68
Appetite control
-111
Energy
-94
Mood
-47
Focus
-86

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Headache
-152
GI discomfort
-31
Dizziness
-129
Fatigue
-51
Nausea
-86

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.2–0.4 mg

Reports span 0.05–2 mg

0.05–0.1 mg
7
0.1–0.2 mg
15
0.2–0.4 mg
23
0.4–0.6 mg
12
0.6–1 mg
7
1–2 mg
1

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing25stacking18side effects11pt-14124

How repeat users are trending

Among repeat reporters, 55% said they felt similar to their last entry, 31% more positive, and 15% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 29 days · Based on 427 repeat reporters

Sources (11)

Published sources linked on the GHK-Cu and PT-141 wiki pages.

  1. Review Article

    GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes

    Pickart L, Margolina A. Cosmetics. 2018

    Source
    Wiki study page →
  2. PubMed

    GHK peptide as a natural modulator of multiple cellular pathways

    Pickart L, Margolina A. Biomed Res Int. 2014

    Source
    Wiki study page →
  3. ClinicalTrials.gov

    GHK-Cu copper peptide studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  4. PubMed

    GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration

    Pickart L, Vasquez-Soltero JM, Margolina A. BioMed research international. 2015

    Source
    Wiki study page →
  5. PubMed

    Biomimetic Hydrogel Scaffolds with Copper Peptide-Functionalized RADA16 Nanofiber Improve Wound Healing in Diabetes

    Yang X, Zhang Y, Huang C, et al. Macromolecular bioscience. 2022

    Source
    Wiki study page →
  6. FDA Drug Label

    VYLEESI (bremelanotide injection) for subcutaneous use - Prescribing Information

    AMAG Pharmaceuticals. FDA Drug Label. 2019

    Source
    Wiki study page →
  7. PubMed

    Bremelanotide: New Drug for Treating Hypoactive Sexual Desire Disorder

    Kingsberg SA, Clayton AH, Portman D, et al. Obstet Gynecol. 2019

    Source
    Wiki study page →
  8. ClinicalTrials.gov

    Bremelanotide (PT-141) studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  9. PubMed

    Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment

    Pettigrew JA, Novick AM. Journal of midwifery & women's health. 2021

    Source
    Wiki study page →
  10. PubMed

    Pharmacologic therapeutic options for sexual dysfunction

    Burton CS, Mishra K. Current opinion in obstetrics & gynecology. 2022

    Source
    Wiki study page →